Because of the global incidence of diabetes and kidney stones, the global urinary tract infection treatment market is expanding rapidly. Moreover, the expanding elderly population and rising prevalence of urinary tract infection (UTI) are likely to drive market expansion. Nevertheless, problems such as undesirable effects associated with UTI medicine use and a lack of public knowledge are projected to stifle expansion in the urinary tract infection therapeutic market. Adverse effects associated with UTI drug use, as well as a lack of knowledge among individuals in poor and undeveloped nations, are likely to stymie the worldwide urinary tract infection therapeutic market's expansion. The prevalence of UTIs (complex UTIs) is predicted to rise throughout the projection period due to an increase in UTI recurrence, increased bacterial resistance in UTI patients, and excessive antibiotic usage. This, in turn, is projected to enhance demand for innovative urinary tract infection treatments (drugs) globally, and this trend is expected to continue during the forecast period, driving market expansion. Furthermore, rising consumer awareness of the link between diabetes and obesity and bladder dysfunction, increased emphasis on the development of novel therapeutics, and the rapid deployment of innovative UTI treatment technologies are among the key trends driving the overall growth of the urinary tract infection therapeutic market.
According to Coherent Market Insights. the global Urinary Tract Infection Therapeutic Market was valued at US$ 8,665.5 Mn in 2021 and is forecast to reach a value of US$ 10,686.5 Mn by 2028 at a CAGR of 3.0% between 2022 and 2028.
Leading Companies in the Urinary Tract Infection Therapeutic Industry:
1. Pfizer
Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sell biopharmaceutical products worldwide.
2. Novartis AG
The company was incorporated in 1996 and is headquartered in Basel, Switzerland. Novartis AG researches, develops, manufactures, and markets healthcare products worldwide.
3. Cipla Inc.
Cipla Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India, the United States, South Africa, and internationally. The company was incorporated in 1935 and is headquartered in Mumbai, India.In October 2019, Cipla Limited announces the acquisition of a novel and patented anti-infective product, Elores, from Venus Remedies Limited for the Indian market to further strengthen its presence in the branded Indian critical care space and as a part of its agenda to contribute to the fight against Anti-Microbial Resistance (AMR). In March 2021, Cipla Therapeutics, a commercial-stage pharmaceutical company, announced entering a strategic partnership to deliver sustained innovation and access to novel antibacterial drugs, particularly against bio-threats.